NASDAQ:GRFS - Nasdaq - US3984384087 - ADR - Currency: USD
7.45
-0.08 (-1.06%)
The current stock price of GRFS is 7.45 USD. In the past month the price decreased by -0.27%. In the past year, price decreased by -18.4%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Grifols SA engages in the production of plasma derivatives. The company is headquartered in Sant Cugat Del Valles, Barcelona and currently employs 23,744 full-time employees. The company went IPO on 2006-05-17. The firm organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
GRIFOLS SA-ADR
Parque Empresarial Can Sant Joan, Avinguda de la Generalitat, 152-158
Sant Cugat del Valles BARCELONA 08174 ES
CEO: Raimon Grifols Roura
Employees: 23505
Company Website: https://www.grifols.com/
Investor Relations: https://www.grifols.com/en/investors
Phone: 34935710000
The current stock price of GRFS is 7.45 USD. The price decreased by -1.06% in the last trading session.
The exchange symbol of GRIFOLS SA-ADR is GRFS and it is listed on the Nasdaq exchange.
GRFS stock is listed on the Nasdaq exchange.
21 analysts have analysed GRFS and the average price target is 14.18 USD. This implies a price increase of 90.4% is expected in the next year compared to the current price of 7.45. Check the GRIFOLS SA-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GRIFOLS SA-ADR (GRFS) has a market capitalization of 5.06B USD. This makes GRFS a Mid Cap stock.
GRIFOLS SA-ADR (GRFS) currently has 23505 employees.
GRIFOLS SA-ADR (GRFS) has a support level at 6.95 and a resistance level at 7.46. Check the full technical report for a detailed analysis of GRFS support and resistance levels.
The Revenue of GRIFOLS SA-ADR (GRFS) is expected to grow by 8.13% in the next year. Check the estimates tab for more information on the GRFS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GRFS does not pay a dividend.
GRIFOLS SA-ADR (GRFS) will report earnings on 2025-02-26, after the market close.
The PE ratio for GRIFOLS SA-ADR (GRFS) is 33.86. This is based on the reported non-GAAP earnings per share of 0.22 and the current share price of 7.45 USD. Check the full fundamental report for a full analysis of the valuation metrics for GRFS.
The outstanding short interest for GRIFOLS SA-ADR (GRFS) is 1.1% of its float. Check the ownership tab for more information on the GRFS short interest.
ChartMill assigns a technical rating of 2 / 10 to GRFS. When comparing the yearly performance of all stocks, GRFS is a bad performer in the overall market: 82.73% of all stocks are doing better.
ChartMill assigns a fundamental rating of 5 / 10 to GRFS. There are concerns on the financial health of GRFS while its profitability can be described as average.
Over the last trailing twelve months GRFS reported a non-GAAP Earnings per Share(EPS) of 0.22. The EPS increased by 162.5% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 2.05% | ||
ROA | 0.71% | ||
ROE | 2.69% | ||
Debt/Equity | 1.65 |
ChartMill assigns a Buy % Consensus number of 74% to GRFS. The Buy consensus is the average rating of analysts ratings from 21 analysts.
For the next year, analysts expect an EPS growth of 14.73% and a revenue growth 8.13% for GRFS